Latest / DDReg Knowledge Capsule / Navigating EMA’s Voluntary Data Submission Pilot for NAMs

Transcript

Navigating EMA’s Voluntary Data Submission Pilot for NAMs · DDReg Knowledge Capsule

• 0:00
  Speaker 1: Welcome to the DD-REG Knowledge Capsule. Imagine walking into a
• 0:04
  Speaker 1: major pharmaceutical testing facility, say, 10 years from now. The
• 0:08
  Speaker 1: cages are empty.
• 0:09
  Speaker 2: Yeah, completely empty. Right?
• 0:11
  Speaker 1: The rats, the mice, the beagles, they are all gone.
• 0:14
  Speaker 1: And in their place, you see rows of microfluidic chips
• 0:17
  Speaker 1: containing beating human heart cells, three-dimensional lung tissues breathing inside incubators,
• 0:24
  Speaker 1: and massive server farms running computational models.
• 0:28
  Speaker 2: Models that simulate millions of biological interactions every single second.
• 0:32
  Speaker 1: Exactly. And that is the future regulators are trying to
• 0:35
  Speaker 1: build today. So whether you are prepping for a high-stakes
• 0:38
  Speaker 1: pharmaceutical strategy meeting, or you are just insanely curious about
• 0:42
  Speaker 1: how the medicines of the future will actually be deemed
• 0:45
  Speaker 1: safe for humans, well, you are in the right place.
• 0:48
  Speaker 1: Today we are diving into a really vital set of
• 0:50
  Speaker 1: source materials, anchored by a detailed October 21, 2026 publication
• 0:53
  Speaker 1: by DD Reg Pharma.
• 0:57
  Speaker 2: Right. And the mission of this deep dive is to
• 0:59
  Speaker 2: explore the EMA, the European Medicines Agency, and their newly
• 1:03
  Speaker 2: launched Voluntary Data Submission Pilot, or VDS as we'll call it.
• 1:08
  Speaker 1: Which is specifically focused on new approach methodologies, or as
• 1:12
  Speaker 1: the industry calls them, NAMs.
• 1:14
  Speaker 2: Yeah, NAMs. And it is a critical juncture for the
• 1:16
  Speaker 2: industry right now. Because to really understand why this October
• 1:21
  Speaker 2: 2026 publication matters, we have to look at the fundamental
• 1:24
  Speaker 2: shift happening in regulatory science. Right.
• 1:27
  Speaker 1: Because for decades, the scientific world has debated the validity
• 1:31
  Speaker 1: of non-animal methods, right? Exactly.
• 1:34
  Speaker 2: We are talking about highly complex in vitro systems, three-dimensional
• 1:38
  Speaker 2: organoids that actually replicate the spatial architecture of human tissue,
• 1:43
  Speaker 2: and microphysiological systems like A liver on a chip that
• 1:46
  Speaker 2: simulates actual blood flow and mechanical stress.
• 1:50
  Speaker 1: Plus it was incredibly advanced in silico computational models.
• 1:54
  Speaker 2: Right. But the core premise we need to establish right
• 1:57
  Speaker 2: out of the gate is that the scientific community is
• 1:59
  Speaker 2: rapidly moving past the question of whether these non-animal methods
• 2:04
  Speaker 2: can generate scientifically credible data. I mean, that debate is
• 2:07
  Speaker 2: essentially over.
• 2:08
  Speaker 1: The science has matured. Mm-hmm. We are no longer just
• 2:11
  Speaker 1: looking at flat, two-dimensional cell cultures in a petri dish
• 2:14
  Speaker 1: that simply die when exposed to a toxin. We are
• 2:17
  Speaker 1: looking at bioengineered microenvironments that react to drugs almost identically
• 2:22
  Speaker 1: to how a human body would.
• 2:23
  Speaker 2: Yeah, and that technological leap, it forces a completely new
• 2:27
  Speaker 2: problem onto the table. Because the most difficult question now
• 2:30
  Speaker 2: is how regulators actually evaluate that new type of evidence consistently.
• 2:35
  Speaker 1: Because they have, what, 80 years of historical baseline data?
• 2:39
  Speaker 1: on how a rat's liver responds to certain chemical structures.
• 2:42
  Speaker 2: Exactly. They know the margins of error. They know the
• 2:45
  Speaker 2: blind spots. But when faced with data generated by a
• 2:49
  Speaker 2: proprietary lab-grown organoid or, say, an AI-driven toxicity model, they
• 2:54
  Speaker 2: lack that massive historical baseline. They have to figure out
• 2:57
  Speaker 2: how to look at this entirely novel data stream and
• 3:00
  Speaker 2: confidently use it to make binding life-or-death decisions about human safety.
• 3:04
  Speaker 1: Right, because regulatory experience simply hasn't kept pace with the
• 3:07
  Speaker 1: rapid evolution of the bioengineering. There is a massive real-world
• 3:12
  Speaker 1: evidence gap.
• 3:13
  Speaker 2: A huge gap. Which brings us to what the EMA
• 3:16
  Speaker 2: is doing.
• 3:17
  Speaker 1: Right. So to understand this shift, we first have to
• 3:19
  Speaker 1: look at the massive, unprecedented sandbox the EMA just created
• 3:24
  Speaker 1: to figure it all out. Okay, let's unpack this. This
• 3:27
  Speaker 1: voluntary data submission pilot, it officially launched in September of 2026.
• 3:33
  Speaker 2: And the window for applications remains open until September 2027.
• 3:36
  Speaker 1: Right. The fundamental idea is that it allows stakeholders, so
• 3:41
  Speaker 1: pharmaceutical companies, contract research organizations, and academic labs, to submit
• 3:46
  Speaker 1: their NAM-derived data to the regulators. But they do it
• 3:49
  Speaker 1: entirely outside of a formal marketing authorization application.
• 3:53
  Speaker 2: And that structural distinction is the entire value proposition of
• 3:57
  Speaker 2: the pilot. Because submitting outside of a formal marketing authorization application,
• 4:01
  Speaker 2: or MAA, it removes the inherent risk of the regulatory process.
• 4:06
  Speaker 1: Right, because in a standard MAA, the environment is highly
• 4:09
  Speaker 1: formalized and, frankly, high pressure.
• 4:11
  Speaker 2: Exactly. A definitive yes or no decision is being made
• 4:14
  Speaker 2: on whether a drug goes to market. If a sponsor
• 4:17
  Speaker 2: includes a highly novel NAM in their safety package, and
• 4:20
  Speaker 2: the regulator is hesitant or just doesn't fully understand the
• 4:23
  Speaker 2: model's limitations, well, the regulator's default position to protect public
• 4:27
  Speaker 2: health is to reject the application. Wow.
• 4:31
  Speaker 1: So there is zero room for experimental dialogue when Drug
• 4:35
  Speaker 1: approval is on the line.
• 4:36
  Speaker 2: None. But with this VDS pilot, the feedback the EMA
• 4:41
  Speaker 2: provides is entirely individual, non-binding, and non-decisional.
• 4:45
  Speaker 1: You know, reading through the DD Reg material, this feels
• 4:49
  Speaker 1: exactly like an exhibition game before the regular sports season starts. Like,
• 4:53
  Speaker 1: if you are a coach, you want to test out
• 4:56
  Speaker 1: your brand new, highly complex plays.
• 4:58
  Speaker 2: The NAMs, in this case.
• 5:00
  Speaker 1: Exactly. The NAMs. You want to run them on the
• 5:03
  Speaker 1: actual field against a real defense to see how they
• 5:06
  Speaker 1: hold up. But you need to do it without risking
• 5:08
  Speaker 1: a loss on your actual permanent record.
• 5:11
  Speaker 2: Because in the pharma world, taking a loss on your
• 5:13
  Speaker 2: record means a rejected MAA, which costs millions of dollars
• 5:17
  Speaker 2: and sets a clinical program back by years. You absolutely
• 5:21
  Speaker 2: need a safe space to run the play.
• 5:23
  Speaker 1: Right.
• 5:24
  Speaker 2: And the beauty of this particular exhibition game is that
• 5:27
  Speaker 2: it is incredibly broad in its scope. I mean, it
• 5:30
  Speaker 2: is not restricted to human medicine. It also applies to
• 5:32
  Speaker 2: veterinary medicines, which rely heavily on animal testing paradigms.
• 5:36
  Speaker 1: Oh, that makes sense.
• 5:37
  Speaker 2: Yeah. So opening this up to a wide range of
• 5:40
  Speaker 2: stakeholders means 2026 will likely be viewed as the pivot
• 5:44
  Speaker 2: point for regulatory acceptance. It is the moment Europe transitioned
• 5:48
  Speaker 2: from offering just broad encouragement for innovative methods to actually
• 5:52
  Speaker 2: building a structured framework.
• 5:54
  Speaker 1: A framework where regulators can learn how specific NAMs answer
• 5:58
  Speaker 1: defined safety questions. without the ticking clock of an approval deadline.
• 6:03
  Speaker 1: But that brings up a huge logistical hurdle. How exactly
• 6:06
  Speaker 1: do you bring a play to this exhibition game?
• 6:09
  Speaker 2: Well, you can't just show up with anything. Right.
• 6:11
  Speaker 1: The EMA isn't just opening their doors and saying, hey,
• 6:14
  Speaker 1: send us your cool science project so we can marvel
• 6:16
  Speaker 1: at them. They require a very specific, highly formalized playbook.
• 6:21
  Speaker 2: Yeah, this is not an open call for interesting technology.
• 6:24
  Speaker 2: The EMA's goal is to learn how this novel data
• 6:26
  Speaker 2: functions within the mechanics of actual regulatory decision-making. Because regulators
• 6:31
  Speaker 2: do not evaluate technology in a vacuum, you know, they
• 6:34
  Speaker 2: evaluate evidence as it applies to a specific claim.
• 6:37
  Speaker 1: Which brings us to the anatomy of a submission. The
• 6:41
  Speaker 1: source material outlines an incredibly rigorous formatting requirement here.
• 6:44
  Speaker 2: Very rigorous, yeah.
• 6:46
  Speaker 1: If a sponsor is selected after submitting their initial expression
• 6:49
  Speaker 1: of interest, they are invited to submit a full briefing package.
• 6:54
  Speaker 2: And the EMA expects this package to be aligned with
• 6:56
  Speaker 2: ECTD Module 2.4.
• 6:58
  Speaker 1: Meaning you can't just send over your raw lab data
• 7:01
  Speaker 1: or like a glossy brochure about your tech.
• 7:03
  Speaker 2: No, not at all. You have to submit that massive,
• 7:06
  Speaker 2: meticulously synthesized, non-clinical overview that you would normally only build
• 7:11
  Speaker 2: for a finalized formal regulatory dossier. It requires a serious
• 7:15
  Speaker 2: investment of time and resources from the sponsor.
• 7:17
  Speaker 1: And the sponsor's checklist for what must be in that
• 7:20
  Speaker 1: package is deeply demanding, right?
• 7:23
  Speaker 2: It is because the EMA has limited this pilot to
• 7:25
  Speaker 2: predefined contexts of use, often abbreviated as COU, and broader
• 7:31
  Speaker 2: regulatory applicability areas, or RAAs. A sponsor must explicitly define
• 7:36
  Speaker 2: the regulatory problem they are trying to solve.
• 7:38
  Speaker 1: And they must define the biological relevance of their model
• 7:41
  Speaker 1: to the human safety question.
• 7:43
  Speaker 2: Exactly. Plus, they have to be entirely transparent about the
• 7:46
  Speaker 2: method's limitations and uncertainties. And crucially, they must explain how
• 7:50
  Speaker 2: this NAM works within a weight-of-evidence approach.
• 7:53
  Speaker 1: Meaning detailing how the data from the microchip combines with
• 7:57
  Speaker 1: other existing data streams to support a scientifically justified conclusion.
• 8:02
  Speaker 1: But I want to push back on this a bit,
• 8:04
  Speaker 1: or at least play devil's advocate here. Because I can
• 8:06
  Speaker 1: imagine method developers listening to this and pulling their hair out.
• 8:10
  Speaker 1: If I have spent a decade creating a technically... sophisticated,
• 8:15
  Speaker 1: mind-blowing microphysiological system. Let's say a perfectly functional artificial human
• 8:20
  Speaker 1: liver on a chip.
• 8:21
  Speaker 2: Okay. A liver on a chip.
• 8:22
  Speaker 1: Right. And it has consistently predicted toxicity better than any
• 8:26
  Speaker 1: rat study in my lab. Shouldn't that technology speak for itself?
• 8:30
  Speaker 1: The data is brilliant. Why do I have to painstakingly
• 8:34
  Speaker 1: spoon-feed the specific regulatory context and all these rigid applicability
• 8:38
  Speaker 1: areas to the EMA?
• 8:40
  Speaker 2: What's fascinating here is the fundamental difference between the mindset
• 8:43
  Speaker 2: of a bioengineer and the mindset of a regulator. I mean,
• 8:46
  Speaker 2: a bioengineer builds a tool to replicate biology. A regulator
• 8:50
  Speaker 2: evaluates risk for a highly specific scenario. I see. Yeah.
• 8:54
  Speaker 2: A tool's acceptability simply cannot be considered independently of what
• 8:58
  Speaker 2: it is specifically intended to demonstrate. Your liver on a
• 9:02
  Speaker 2: chip might be an absolute triumph of bioengineering, but to
• 9:05
  Speaker 2: a regulatory agency, it is effectively useless because if you
• 9:08
  Speaker 2: haven't clearly defined the specific regulatory question it is meant
• 9:12
  Speaker 2: to answer.
• 9:12
  Speaker 1: So a context of use isn't just saying, hey, this
• 9:15
  Speaker 1: tests for liver toxicity.
• 9:16
  Speaker 2: No, it has to be granular. It is saying this
• 9:19
  Speaker 2: specific microfluidic chip will be used to screen for late-stage
• 9:23
  Speaker 2: drug-induced liver injury in adult humans, specifically to replace the
• 9:27
  Speaker 2: standard 28-day repeated-dose rat toxicity study for small-molecule cardiovascular drugs. Wow.
• 9:34
  Speaker 1: Okay, that makes perfect sense. A brilliant method applied to
• 9:36
  Speaker 1: a poorly defined regulatory question is still a failed submission.
• 9:40
  Speaker 1: It is like inventing the most advanced calculator in the world,
• 9:43
  Speaker 1: handing it to someone, but refusing to tell them what
• 9:45
  Speaker 1: math equation you are actually trying to solve.
• 9:47
  Speaker 2: That's exactly it. And the EMA's pilot is specifically designed
• 9:51
  Speaker 2: to force developers to articulate that equation. They need to
• 9:55
  Speaker 2: see the endpoint, the biological mechanism, the validation status, and
• 9:59
  Speaker 2: how this new method works. fits into the existing regulatory gap.
• 10:02
  Speaker 1: And if a sponsor is using a weight-of-evidence approach?
• 10:05
  Speaker 2: Then the EMA needs to see how an in-silico computer
• 10:09
  Speaker 2: model predicting chemical binding physically links up with the biological
• 10:12
  Speaker 2: reaction shown on the organoid. They need to see the
• 10:15
  Speaker 2: practical interlocking application of the science, not just the technical
• 10:19
  Speaker 2: specifications of the chip.
• 10:21
  Speaker 1: Which brings up a major pitfall highlighted in the DDReg article.
• 10:24
  Speaker 1: Because defining that specific regulatory question is so critical, you
• 10:29
  Speaker 1: could have a groundbreaking NAM, you could have pristine data,
• 10:33
  Speaker 1: but you might actually find that this brand new VDS
• 10:35
  Speaker 1: pilot is the completely wrong place for your specific question.
• 10:40
  Speaker 2: Right. The VDS pilot is not some universal replacement for
• 10:44
  Speaker 2: all existing EMA procedures, just because your program happens to
• 10:48
  Speaker 2: involve a non-animal method.
• 10:50
  Speaker 1: It is just one specific piece of a much larger
• 10:53
  Speaker 1: regulatory ecosystem.
• 10:55
  Speaker 2: Exactly. And if developers don't understand how the pieces fit together,
• 10:59
  Speaker 2: they will waste years of effort. The source material details
• 11:02
  Speaker 2: several established alternatives to the VDS pilot that sponsors must consider.
• 11:07
  Speaker 1: Like the Innovation Task Force, or ITF.
• 11:10
  Speaker 2: Yeah, the ITF. That pathway is designed for early, informal
• 11:14
  Speaker 2: dialogue on innovative technologies where there's a high degree of
• 11:17
  Speaker 2: regulatory uncertainty and the technology is still maturing. Then you
• 11:21
  Speaker 2: have scientific advice.
• 11:23
  Speaker 1: Which is much more formal, right? Very formal.
• 11:25
  Speaker 2: It is strictly for product-specific or development-specific regulatory questions, where
• 11:30
  Speaker 2: a sponsor needs to know if their method is acceptable
• 11:32
  Speaker 2: for a specific drug they are actively trying to approve.
• 11:35
  Speaker 1: And there are even pathways for the methods themselves, beyond
• 11:38
  Speaker 1: just the drugs.
• 11:39
  Speaker 2: Yes, there is qualification advice, which is for sponsors seeking
• 11:43
  Speaker 2: a formal, official qualification pathway for a specific methodology to
• 11:48
  Speaker 2: be recognized across the board. And finally, you have the
• 11:51
  Speaker 2: VDS pilot, which, as we discussed, is highly specific.
• 11:55
  Speaker 1: It is for NAM data that requires regulatory experience and
• 11:58
  Speaker 1: confidence building outside of a marketing authorization application. You know,
• 12:02
  Speaker 1: it is exactly like navigating the health care system. Think
• 12:05
  Speaker 1: about it.
• 12:06
  Speaker 2: How so?
• 12:07
  Speaker 1: Well, you wouldn't go to the emergency room. which in
• 12:09
  Speaker 1: this analogy would be formal scientific advice, for a minor scrape.
• 12:13
  Speaker 1: And you definitely wouldn't go to a quick walk-in clinic
• 12:16
  Speaker 1: like the Innovation Task Force if you needed major complex
• 12:19
  Speaker 1: open-heart surgery.
• 12:20
  Speaker 2: Right, right.
• 12:21
  Speaker 1: You have to pick the right door for your specific
• 12:23
  Speaker 1: medical need. Otherwise, your symptoms are going to be evaluated
• 12:26
  Speaker 1: by the wrong specialists against entirely the wrong criteria.
• 12:30
  Speaker 2: That is a great way to put it. And the
• 12:32
  Speaker 2: EMA recognizes how confusing this ecosystem can be, which is
• 12:35
  Speaker 2: why they explicitly built a validation step into the VDS process.
• 12:39
  Speaker 2: When a sponsor submits an expression of interest for the
• 12:41
  Speaker 2: VDS pilot, the EMA reviews that initial concept.
• 12:44
  Speaker 1: And during this validation, they might realize the sponsor's objective
• 12:47
  Speaker 1: is misplaced.
• 12:48
  Speaker 2: Exactly. They will step in and say, based on what
• 12:50
  Speaker 2: you are trying to achieve, you shouldn't be in this pilot.
• 12:53
  Speaker 2: You actually need product-specific answers, so we are redirecting you
• 12:56
  Speaker 2: to scientific advice.
• 12:57
  Speaker 1: So if you pick the wrong door, the bouncer steps
• 13:00
  Speaker 1: in and politely points you down the street to the
• 13:02
  Speaker 1: right club. That saves everyone a massive headache. But While
• 13:06
  Speaker 1: Europe seems to have its ecosystem and its different doors
• 13:09
  Speaker 1: clearly labeled with this pilot, drug development is inherently a
• 13:13
  Speaker 1: global game. Oh, absolutely.
• 13:14
  Speaker 2: A sponsor rarely spends a billion dollars developing a drug
• 13:18
  Speaker 2: just to launch it in Europe. Right.
• 13:20
  Speaker 1: They need it approved in the U.S. by the FDA
• 13:22
  Speaker 1: and in the U.K. by the MHRA. So if Europe
• 13:25
  Speaker 1: is asking for a specific playbook for this exhibition game,
• 13:29
  Speaker 1: what are the Americans and the British asking for?
• 13:31
  Speaker 2: This is where the landscape becomes incredibly complex and, frankly,
• 13:34
  Speaker 2: treacherous for global sponsors. Because the global regulatory direction is
• 13:39
  Speaker 2: converging on the macro level, everyone agrees that the industry
• 13:42
  Speaker 2: must move towards scientifically justified non-animal methods.
• 13:46
  Speaker 1: But the mechanisms are different.
• 13:47
  Speaker 2: Entirely different. The actual frameworks and underlying regulatory philosophies being
• 13:51
  Speaker 2: deployed by the different major agencies are diverging significantly.
• 13:55
  Speaker 1: Okay, let's look at the U.S. first. According to the
• 13:59
  Speaker 1: DD Reg publication, the FDA issued draft guidance back in
• 14:02
  Speaker 1: March 2026, and their approach seems intensely focused on a
• 14:06
  Speaker 1: validation-oriented framework.
• 14:08
  Speaker 2: Yes, they want deep technical characterization and fit-for-purpose considerations. Then
• 14:14
  Speaker 2: in September 2026, the FDA launched this NAM database of
• 14:18
  Speaker 2: use case examples.
• 14:20
  Speaker 1: But the crucial detail there is that these are illustrative,
• 14:23
  Speaker 1: non-binding examples based on past reviews.
• 14:26
  Speaker 2: Right.
• 14:27
  Speaker 1: Just because a specific liver on a chip is in
• 14:29
  Speaker 1: that FDA database doesn't mean you can just buy that
• 14:32
  Speaker 1: chip and automatically assume it is approved for your drug
• 14:35
  Speaker 1: safety package. Exactly.
• 14:37
  Speaker 2: You still have to prove it for your specific context.
• 14:40
  Speaker 2: The FDA's framework places a massive emphasis on strict, rigid
• 14:45
  Speaker 2: validation principles to establish confidence.
• 14:47
  Speaker 1: Why so strict?
• 14:48
  Speaker 2: The logic behind this stems from the U.S. regulatory and
• 14:51
  Speaker 2: legal culture, which historically relies on highly standardized, reproducible benchmarks
• 14:57
  Speaker 2: to mitigate legal and safety risks. They want to see
• 14:59
  Speaker 2: the technical math behind the method.
• 15:02
  Speaker 1: Got it.
• 15:03
  Speaker 2: Now, contrast that strict technical validation with the UK's MHRA.
• 15:09
  Speaker 2: They also issued guidance in March 2026, but they took
• 15:12
  Speaker 2: a very different philosophical approach. The MHRA is heavily emphasizing
• 15:17
  Speaker 2: the totality of the evidence package.
• 15:20
  Speaker 1: Which means they are looking at the forest, not just
• 15:22
  Speaker 1: the individual trees.
• 15:23
  Speaker 2: Precisely. The MHRA has explicitly stated that they do not
• 15:27
  Speaker 2: expect a simple one-to-one replacement of individual animal studies. They
• 15:32
  Speaker 2: recognize that biology is messy and complex. They aren't looking
• 15:35
  Speaker 2: for a single non-animal test that perfectly mimics a flawed
• 15:39
  Speaker 2: 28-day rat test.
• 15:41
  Speaker 1: Instead, they are taking a pragmatic, mechanistic view.
• 15:44
  Speaker 2: Right. They evaluate whether the overall data package, when viewed holistically,
• 15:49
  Speaker 2: combining in vitro, in silico, and any available clinical data,
• 15:53
  Speaker 2: adequately addresses the fundamental safety profile of the drug.
• 15:57
  Speaker 1: Here's where it gets really interesting. Because if I am
• 15:59
  Speaker 1: a global pharma sponsor, I am looking at a massive
• 16:03
  Speaker 1: strategic nightmare. I have the FDA demanding strict, robust technical
• 16:07
  Speaker 1: validation of the specific tool.
• 16:09
  Speaker 2: Right.
• 16:10
  Speaker 1: I have the MHRA saying, don't worry about mimicking the
• 16:13
  Speaker 1: rat perfectly, just show us the holistic weight of the evidence.
• 16:17
  Speaker 1: And then I have the EMA asking me to jump
• 16:19
  Speaker 1: into this highly structured VDS pilot program Just to build
• 16:22
  Speaker 1: their confidence. Aren't sponsors just going to be running in
• 16:26
  Speaker 1: circles trying to satisfy three completely different philosophies?
• 16:29
  Speaker 2: If we connect this to the bigger picture, that friction
• 16:32
  Speaker 2: is the defining challenge of the next decade of drug development.
• 16:36
  Speaker 2: Because the same NAM will require different documentation and contextual
• 16:40
  Speaker 2: justification depending on the region.
• 16:43
  Speaker 1: Meaning I can't just photocopy my submission dossier for the
• 16:46
  Speaker 1: exact same drug and data?
• 16:48
  Speaker 2: Not at all. Ugh. This is why a global NAM
• 16:51
  Speaker 2: strategy must be formulated early. You cannot treat EMA, FDA,
• 16:56
  Speaker 2: and MHRA submissions as interchangeable. The FDA might demand a
• 17:00
  Speaker 2: deep dive into the technical reproducibility of your organoid across
• 17:04
  Speaker 2: different lab sites.
• 17:05
  Speaker 1: While the MHRA wants a broader narrative?
• 17:07
  Speaker 2: Yes, about how that organoid's data proves overall human safety
• 17:11
  Speaker 2: when combined with chemical structure analysis. And the EMA wants
• 17:15
  Speaker 2: you to run it through their VDS pilot first, just
• 17:17
  Speaker 2: to establish the baseline context of use. Wow.
• 17:20
  Speaker 1: You aren't just managing scientists in lab coats anymore. You
• 17:23
  Speaker 1: are managing a highly nuanced global regulatory translation effort.
• 17:27
  Speaker 2: And that translation phase is where the strategic battle is
• 17:30
  Speaker 2: won or lost. A sponsor receiving positive, encouraging feedback from
• 17:34
  Speaker 2: the EMA's VDS pilot cannot just turn around and tell
• 17:36
  Speaker 2: their board of directors that their method is globally qualified. Right.
• 17:40
  Speaker 1: It simply means they have taken a successful first step
• 17:42
  Speaker 1: in Europe. Exactly.
• 17:43
  Speaker 2: The feedback might highlight that they still need to refine
• 17:45
  Speaker 2: their context of use or generate more reproducibility data for
• 17:49
  Speaker 2: the FDA or improve their weight of evidence rationale for
• 17:52
  Speaker 2: the MHRA long before they ever step foot near a
• 17:55
  Speaker 2: formal marketing authorization application.
• 17:58
  Speaker 1: So what does this all mean? When we synthesize this
• 18:01
  Speaker 1: DD-REG publication and look at the rapidly evolving landscape, the
• 18:06
  Speaker 1: primary takeaway for you, the listener, is this. The industry's
• 18:10
  Speaker 1: shift to non-animal methods is absolutely not a simple one-to-one swap.
• 18:15
  Speaker 2: No, not at all.
• 18:16
  Speaker 1: We are not just taking a beagle out of a
• 18:18
  Speaker 1: cage and replacing it with a microchip. The entire paradigm
• 18:21
  Speaker 1: of safety testing is moving toward incredibly sophisticated evidence strategies.
• 18:27
  Speaker 1: We are looking at a future where NAMs, mechanistic data,
• 18:30
  Speaker 1: and computational models are combined.
• 18:33
  Speaker 2: And navigating that profound complexity is exactly why organizations like
• 18:36
  Speaker 2: DDREG exist. Their role is to support sponsors through this
• 18:40
  Speaker 2: massive transition. They help developers proactively map out those crucial
• 18:44
  Speaker 2: contexts of use, assess where the regulatory gaps are, and
• 18:48
  Speaker 2: strategically navigate the differing expectations of the EMA, the FDA,
• 18:52
  Speaker 2: and the MHRA.
• 18:54
  Speaker 1: So a sponsor doesn't spend years walking through the wrong door.
• 18:57
  Speaker 1: It is a brave new world of regulatory science requiring
• 19:01
  Speaker 1: a completely new playbook.
• 19:03
  Speaker 2: It really is.
• 19:03
  Speaker 1: Well, to wrap things up, I want to leave you
• 19:06
  Speaker 1: with one final provocative thought to mull over as you
• 19:10
  Speaker 1: digest all of this. We talked about the UK's MHRA
• 19:14
  Speaker 1: explicitly moving away from expecting a one-to-one replacement of animal studies,
• 19:18
  Speaker 1: choosing instead to look at the holistic underlying biology.
• 19:22
  Speaker 2: Right.
• 19:23
  Speaker 1: If global regulators are no longer expecting a single non-animal
• 19:27
  Speaker 1: method to perfectly replicate a single animal study, Will we
• 19:31
  Speaker 1: eventually reach a point where we trust the mechanistic pathways
• 19:34
  Speaker 1: mapped by an AI or computational model even more than
• 19:38
  Speaker 1: we trust traditional biological observations? Are we moving from observing
• 19:42
  Speaker 1: biology to completely simulating it?
• 19:46
  Speaker 2: That is the technological horizon we are rapidly heading toward.
• 19:50
  Speaker 1: Thank you so much for joining us for this deep
• 19:51
  Speaker 1: dive into the DDReg Knowledge Capsule. We hope this exploration
• 19:55
  Speaker 1: has given you a much clearer map of the future
• 19:58
  Speaker 1: regulatory landscape. Keep questioning, keep exploring, and we will see
• 20:02
  Speaker 1: you on the next one.